It’s very clear from this report that the FDA’s repeated warnings have caused many doctors to turn away from power morcellators for gynecological surgeries.
New York, New York (PRWEB) March 18, 2015
In the year since the U.S. Food & Drug Administration (FDA) first warned against the use of power morcellators (http://www.morcellatorlawsuit2015.com) in gynecological surgeries, it appears that use of the devices to perform hysterectomies and fibroid removal procedures is on the decline. According to a report from The Wall Street Journal, many physicians are now choosing to perform a procedure known as “mini-laparotomy," in which the uterus is removed through a small incision above the pubic bone, while about a quarter reported that they are performing more open hysterectomies. The report also indicated that the shift towards alternative procedures does not appear to have coincided with a rise in surgical complications, as some had feared.*
“It’s very clear from this report that the FDA’s repeated warnings have caused many doctors to turn away from power morcellators for gynecological surgeries. We are pleased by this news, as the agency has clearly stated that uterine morcellation has the potential to spread and upstage undetected uterine cancers,” says Sandy A. Liebhard LLP, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancer following surgery with a power morcellator.
Power Morcellators and Cancer
Power morcellators are used in minimally-invasive hysterectomies and fibroid removal procedures to shred tissue so that it may be removed through a small abdominal incision. On April 17, 2014, the FDA issued a public alert which discouraged doctors from using the devices in gynecological procedures, due to their potential to spread undetected uterine cancers. According to the agency, an estimated 1 in 350 women undergoing surgery to remove fibroids have undiagnosed cancer. These malignancies are extremely difficult to detect prior to surgery, and their dissemination via uterine morcellation can greatly reduce a woman’s chance of long-term survival, the FDA said.**
The FDA issued a second notification in November 2014, which warned against the use of power morcellators in the majority of women who require hysterectomy and fibroid removals. The agency also asked morcellator manufacturers to add a new black box warning – the strongest possible safety notice – regarding this life-threatening complication to their labels.
Alleged victims of uterine cancers that were spread via a power morcellator may be entitled to compensation for their injury-related damages. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLPs website, or call the Firm directly for a free, no-obligation case review at 800-511-5092.
*nasdaq.com/article/warning-prompts-shift-in-surgeries-on-women-20150316-01218, Wall Street Journal (via Dow Jones News Service), March 16, 2015
**fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htm, FDA, April 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP